Please assess the completion status of the following clinical trial:

Trial Title: Regulation of Intestinal and Hepatic Lipoprotein Secretion by Resveratrol

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Men and women, aged 23 to 60 years~2. Fasting plasma triglycerides between 2.0 and 5.0 mmol/l~3. Body mass index 25 kg/m2 to 35 kg/m2~4. Minimum body weight 64kg~5. Hemoglobin above 130g/L.~6. Research volunteers must be able to provide informed consent and be willing to comply with protocol requirements.~7. HOMA-IR (a measure of insulin resistance calculated from fasting blood glucose and insulin) \>4.0.~   .~Exclusion Criteria:~1. Subject has a history of hepatitis/hepatic disease that has been active within the previous two years.~2. Any significant active (over the past 12 months) disease of the gastrointestinal, pulmonary, neurological, renal (Cr \> 1.5 mg/dL), genitourinary, hematological systems, or has severe uncontrolled treated or untreated hypertension (sitting diastolic BP \> 90 or systolic \>140) or proliferative retinopathy~3. Any dehydration or excessive vomiting~4. History of diabetes or 75g OGTT indicative of diabetes.~5. Cancer or history of cancer~6. Any history of a MI or clinically significant, active, cardiovascular history including a history of arrhythmia's or conduction delays on ECG, unstable angina, or decompensated heart failure.~7. Any active medical illness~8. Any laboratory values: AST \> 2x ULN; ALT \> 2x ULN TSH\>5mU/l or \<0.01 mU/l~9. Any clinically relevant abnormal blood/urine screening test results that are outside of the normal reference range and are significant to the investigator will be excluded~10. Any current hormonal disorder or history or hormonal disorders~11. Any bleeding disorders or autoimmune conditions~12. Any allergies to any of the ingredients in the study product or placebo ie: hypersensitivity to resveratrol, grapes, red wine, red wine polyphenols and microcrystalline microcellulose~13. Current addiction to alcohol or substances of abuse as determined by the investigator.~14. Mental incapacity, unwillingness or language barrier precluding adequate understanding or cooperation~15. Taking any prescription or non-prescription medications at the time of the study~16. Taking any natural health products during the course of the study~17. Having donated blood three months prior to and three months post study procedures~18. A pregnancy test will be performed 1 to 3 days prior to each study in all female subjects (visit #4, and visit #7 before taking study drug). Those who test positive for pregnancy will be excluded.~19. If you are breast-feeding or lactating you will be excluded from the study.~20. Women taking the oral contraceptive pill will be excluded from the study.~21. All current smokers or those who have smoked more than 1 pack per day for 5 years or more.~22. Those with ferritin levels below 50 ug/L will be excluded~23. Study Participants who experience serious adverse event or who no longer satisfy the inclusion /exclusion criteria during the trial will be withdrawn

- Gender: ALL
- Minimum Age: 23 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Resveratrol (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete